Trial Profile
A retrospective, observational study to evaluate the efiicacy and safety of Brentuximab Vedotin in patients with relapsed/refractory Hodgkins' lymphoma: a real life experience
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 31 Jan 2017 New trial record
- 06 Dec 2016 Results of preliminary analysis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.